e-learning
resources
Vienna 2009
Monday, 14.09.2009
Pathobiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice
Y. Hara, N. Gambaryan, Y. Sassi, P. Dorfmüller, S. Eddahibi, A. M. Lompré, M. Humbert, J. S. Hulot (Paris, Le Plessis Robinson, Clamart, France)
Source:
Annual Congress 2009 - Pathobiology of pulmonary hypertension
Session:
Pathobiology of pulmonary hypertension
Session type:
Oral Presentation
Number:
1584
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Hara, N. Gambaryan, Y. Sassi, P. Dorfmüller, S. Eddahibi, A. M. Lompré, M. Humbert, J. S. Hulot (Paris, Le Plessis Robinson, Clamart, France). The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice. Eur Respir J 2009; 34: Suppl. 53, 1584
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
TSC1/mTOR pathway promotes hypoxia-induced pulmonary hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
Role of anti-proliferative therapy in PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Targeted gene delivery of BMPR2 attenuates pulmonary hypertension
Source: Eur Respir J 2012; 39: 329-343
Year: 2012
Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH},
Source: Eur Respir J 2012; 40: 618-629
Year: 2012
Tankyrase(TNKS) inhibiting autophagy promotes the TGF-ß induced EMT process in vitro and Bleomycin(BLM) induced pulmonary fibrosis in rats
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Treatment effects of Rho-kinase (Rock) inhibition
vs.
phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006
The hsp90 inhibitor, 17-AAG prevents and reverses the increases in lung calcineurin expression and activity associated with monocrotaline-induced right ventricular hypertrophy
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
TrkB expression is altered in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 606s
Year: 2007
A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH)
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept